Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

Irreversible kinase inhibitors gain traction

The approval of Boehringer Ingelheim's anticancer drug afatinib highlights the growing enthusiasm for once-shunned irreversible kinase inhibitors.

This is a preview of subscription content, access via your institution

Relevant articles

Open Access articles citing this article.

Access options

Buy article

Get time limited or full article access on ReadCube.

$32.00

All prices are NET prices.

Authors

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Sanderson, K. Irreversible kinase inhibitors gain traction. Nat Rev Drug Discov 12, 649–651 (2013). https://doi.org/10.1038/nrd4103

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/nrd4103

This article is cited by

Search

Quick links

Nature Briefing: Cancer

Sign up for the Nature Briefing: Cancer newsletter — what matters in cancer research, free to your inbox weekly.

Get what matters in cancer research, free to your inbox weekly. Sign up for Nature Briefing: Cancer